
OSMT
Healthcare · Pharmaceuticals · $92.5M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2021
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 15, 2021 | After the close | -0.32 | -0.28 | +11.1% |
| Aug 16, 2021 | After the close | -0.14 | -0.28 | -100.0% |
| May 13, 2021 | After the close | -0.23 | -0.15 | +36.2% |
| Mar 30, 2021 | After the close | -0.24 | -0.88 | -266.7% |
| Nov 10, 2020 | After the close | -0.20 | -0.14 | +30.0% |
| Aug 11, 2020 | After the close | -0.17 | -0.22 | -32.0% |
| May 12, 2020 | After the close | -0.19 | -0.05 | +74.0% |
| Mar 18, 2020 | After the close | -0.06 | -0.51 | -716.0% |
| Nov 14, 2019 | After the close | -0.17 | -2.15 | -1128.6% |
| Aug 8, 2019 | After the close | -0.04 | -2.37 | -5825.0% |
| May 9, 2019 | After the close | -0.11 | -0.12 | -9.1% |
| Mar 27, 2019 | After the close | -0.20 | -0.07 | +66.3% |
| Oct 19, 2018 | After the close | — |
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the…
| -0.10 |
| — |